Literature DB >> 34239225

The Insights of Radical Science in the CRISPR Gene-Editing Era: A History of Science for the People and the Cambridge Recombinant DNA Controversy.

Alyssa Botelho1.   

Abstract

In the wake of controversy over human embryonic gene-editing with CRISPR/Cas9 technology, scientists and commentators have looked repeatedly to the 1975 Asilomar Conference on Recombinant DNA (rDNA) as a model for adjudicating gene-editing today. STS scholars, however, have long critiqued Asilomar as a case of insular scientific self-regulation. Looking beyond Asilomar, other histories from the early biotech years offer fresh insights for those working to create a socially responsible biotechnological practice today. Some of the first scientists to approach genetic engineering with a deep understanding of power and social equity were the biologists in the radical movement Science for the People (SftP). In 1976, SftP learned that Harvard University was planning to build a high-containment facility for rDNA research on its Cambridge campus, and fostered a unique moment of democratic technoscientific governance in their community. The organization's radical framework for understanding and regulating rDNA differed from Asilomar's liberal approach in important ways. While their colleagues at Asilomar ignored the social consequences of rDNA, SftP biologists produced incisive analyses of genetic reductionism, the commercialization of biotechnology, and the public regulation of science-and shared their ideas widely. Along the way, they fostered intellectual connections with an early community of radical and feminist science studies scholars who were investigating emerging issues around genetic engineering. As such, SftP's history offers a sharper understanding of how radical scientists engaged with early STS scholars, as well as profound insights for those who are pursuing an equitable gene-editing landscape in the CRISPR era.

Entities:  

Keywords:  Asilomar; CRISPR; Science for the People; biotechnology; genetic engineering; radical science; recombinant DNA

Year:  2019        PMID: 34239225      PMCID: PMC8259112          DOI: 10.1080/09505431.2019.1623190

Source DB:  PubMed          Journal:  Sci Cult (Lond)        ISSN: 0950-5431


  28 in total

1.  Threat to US genetic engineering.

Authors:  Graham Chedd
Journal:  New Sci       Date:  1976-07-01       Impact factor: 0.319

2.  Dealing with experts: the recombinant DNA debate.

Authors:  Bob Park; Scott Thacher
Journal:  Sci People       Date:  1977 Sep-Oct

3.  Recombinant DNA: Cambridge City Council votes moratorium.

Authors:  Barbara J Culliton
Journal:  Science       Date:  1976-07-23       Impact factor: 47.728

4.  Impure science: AIDS, activism, and the politics of knowledge.

Authors:  S Epstein
Journal:  Med Soc (Berkeley)       Date:  1996

5.  Bitter fight over CRISPR patent heats up.

Authors:  Heidi Ledford
Journal:  Nature       Date:  2016-01-21       Impact factor: 49.962

6.  Start-ups fight for a place in Boston's biotech hub.

Authors:  Heidi Ledford
Journal:  Nature       Date:  2015-06-11       Impact factor: 49.962

7.  CRISPR gene-editing tested in a person for the first time.

Authors:  David Cyranoski
Journal:  Nature       Date:  2016-11-24       Impact factor: 49.962

8.  Summary statement of the Asilomar conference on recombinant DNA molecules.

Authors:  P Berg; D Baltimore; S Brenner; R O Roblin; M F Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

9.  New diseases in new niches.

Authors:  J King
Journal:  Nature       Date:  1978-11-02       Impact factor: 49.962

10.  Biotechnology. A prudent path forward for genomic engineering and germline gene modification.

Authors:  David Baltimore; Paul Berg; Michael Botchan; Dana Carroll; R Alta Charo; George Church; Jacob E Corn; George Q Daley; Jennifer A Doudna; Marsha Fenner; Henry T Greely; Martin Jinek; G Steven Martin; Edward Penhoet; Jennifer Puck; Samuel H Sternberg; Jonathan S Weissman; Keith R Yamamoto
Journal:  Science       Date:  2015-03-19       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.